Next Gen mRNA delivery (LipidGenex)

During the COVID-19 pandemic, mRNA vaccines were a game-changer emerging as the front runner to combat SARS-COV-2. Beyond vaccines, this technology holds promise for other therapeutics. However, mRNA is fragile and easily degraded by our natural defences so cannot be injected directly into the body. Lipid nanoparticles (LNPs) provide a protective envelope that can shield the mRNA to be transported to its intended target. The design of new lipid molecules that can act to protect the mRNA cargo is crucial.

These lipid nanoparticles can be designed to increase efficacy and specificity and to reduce toxicity of the mRNA therapy.